NASDAQ:AUTL

Autolus Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy AUTL

*Your capital is at risk

$1.48

-0.130 (-8.07%)

At Close: Jul 13, 2026

Autolus Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 10.66M and sold 0 AUTL shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	10.66M shares
● Sell	0 shares
100% Buy Activity Weak Negative Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 29, 2026 Buy	Share Option (Right to Buy) A-Award	Young William D Director	Director	47 500 Value: $76.5K
Jun 29, 2026 Buy	Restricted Share Units A-Award	Young William D Director	Director	31 667 Value: $52.3K
Jun 29, 2026 Buy	Share Option (Right to Buy) A-Award	Rao Madduri Ravin Director	Director	47 500 Value: $76.5K
Jun 29, 2026 Buy	Restricted Share Units A-Award	Rao Madduri Ravin Director	Director	31 667 Value: $52.3K
Jun 29, 2026 Buy	Share Option (Right to Buy) A-Award	Richardson Ryan Director	Director	47 500 Value: $76.5K
Jun 29, 2026 Buy	Restricted Share Units A-Award	Richardson Ryan Director	Director	31 667 Value: $52.3K
Jun 29, 2026 Buy	Share Option (Right to Buy) A-Award	Leiderman Elisabeth Director	Director	47 500 Value: $76.5K
Jun 29, 2026 Buy	Restricted Share Units A-Award	Leiderman Elisabeth Director	Director	31 667 Value: $52.3K
Jun 29, 2026 Buy	Share Option (Right to Buy) A-Award	Iannone Robert Director	Director	47 500 Value: $76.5K
Jun 29, 2026 Buy	Restricted Share Units A-Award	Iannone Robert Director	Director	31 667 Value: $52.3K
Jun 29, 2026 Buy	Share Option (Right to Buy) A-Award	Butitta Cynthia M Director	Director	47 500 Value: $76.5K
Jun 29, 2026 Buy	Restricted Share Units A-Award	Butitta Cynthia M Director	Director	31 667 Value: $52.3K
Jun 29, 2026 Buy	Share Option (Right to Buy) A-Award	Bain Linda Director	Director	47 500 Value: $76.5K
Jun 29, 2026 Buy	Restricted Share Units A-Award	Bain Linda Director	Director	31 667 Value: $52.3K
Jun 29, 2026 Buy	Share Option (Right to Buy) A-Award	Azelby Robert Director	Director	47 500 Value: $76.5K
Jun 29, 2026 Buy	Restricted Share Units A-Award	Azelby Robert Director	Director	31 667 Value: $52.3K
Jun 29, 2026 Buy	Share Option (Right to Buy) A-Award	Bonney Michael W Director	Director	47 500 Value: $76.5K
Jun 29, 2026 Buy	Restricted Share Units A-Award	Bonney Michael W Director	Director	31 667 Value: $52.3K
Mar 18, 2026 Buy	Share Option (right to buy)	Richardson Ryan Director	Director	80 000 Value: $112.8K
Mar 18, 2026 Buy	American Depositary Shares	Swan Alexander Chief Human Resources Officer	Officer	41 343 Value: $59.9K
Mar 18, 2026 Buy	Share Option (right to buy)	Swan Alexander Chief Human Resources Officer	Officer	39 246 Value: $468.6K
Mar 18, 2026 Buy	Share Option (right to buy)	Swan Alexander Chief Human Resources Officer	Officer	16 470 Value: $491.8K
Mar 18, 2026 Buy	Share Option (right to buy)	Swan Alexander Chief Human Resources Officer	Officer	18 960 Value: $229.2K
Mar 18, 2026 Buy	Share Option (right to buy)	Swan Alexander Chief Human Resources Officer	Officer	40 000 Value: $268.0K
Mar 18, 2026 Buy	Share Option (right to buy)	Swan Alexander Chief Human Resources Officer	Officer	75 000 Value: $423.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT AUTOLUS THERAPEUTICS PLC

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a program...

Read Full Profile Here